Trex Wind-Down, Inc.
TMBRDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001504167
Trex Wind-Down, Inc. was delisted in 2023; its insiders filed their last Form 4 on Aug 22, 2023; 11 institutions reported holding it in 13F filings for Q3 2023, worth $1.63M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Trex Wind-Down, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Trex Wind-Down, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Koconis John | CEO & Chairman | 70,785 | Aug 22, 2023 | 0 |
| Lucchese Joseph | EVP & CFO | 35,193 | Aug 22, 2023 | 0 |
| Mendelsohn Alan | EVP & CMO | 35,393 | Aug 22, 2023 | 0 |
| Cohen David E | Director | 6,100 | Apr 18, 2023 | 0 |
| Sitar Edward J | Director | 11,127 | Apr 18, 2023 | 0 |
| Pirozzi Gianluca | Director | 6,100 | Apr 18, 2023 | 0 |
| Gaal Lubor | Director | 6,100 | Apr 18, 2023 | 0 |
| Rome Zachary | Director | 59,696 | Apr 15, 2022 | 0 |
| TardiMed Sciences LLC | 10% Owner | 3,508,567 | Sep 2, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2021 (view filing)4:23 PM ET | Dec 15 | 1 day | Koconis JohnCEO & President | PPurchaseCommon Stock, par value $0.001 per share | +20.0K | $0.3843 | +$7.69K | New position20.0K after | |
| Nov 24, 2021 (view filing)4:11 PM ET | Nov 23 | 1 day | Mendelsohn AlanChief Medical Officer | PPurchaseCommon Stock, par value $0.001 per share | +10.0K | $0.47 | +$4.70K | New position10.0K after | |
| Nov 24, 2021 (view filing)4:07 PM ET | Nov 23 | 1 day | Sitar Edward JDirector | PPurchaseCommon Stock, par value $0.001 per share | +15.0K | $0.46 | +$6.90K | New position15.0K after | |
| Sep 2, 2021 (view filing) | Sep 2 | Same day | TardiMed Sciences LLC10% Owner | SSaleCommon Stock, par value $0.001 per share | −225.0K | $0.94 | −$211.5K | −6.0%3.51M after | |
| Sep 1, 2021 (view filing) | Aug 30-Sep 1 | 2 days | TardiMed Sciences LLC10% Owner | SSaleCommon Stock, par value $0.001 per share | −400.5K | $0.9188 | −$368.0K | −9.7%3.73M after | 3 lots |
| Aug 26, 2021 (view filing) | Aug 24-26 | 2 days | TardiMed Sciences LLC10% Owner | SSaleCommon Stock, par value $0.001 per share | −300.0K | $0.92 | −$276.0K | −6.8%4.13M after | 3 lots |
| Aug 20, 2021 (view filing) | Aug 18-20 | 2 days | TardiMed Sciences LLC10% Owner | SSaleCommon Stock, par value $0.001 per share | −175.0K | $0.96 | −$168.0K | −3.8%4.43M after | 3 lots |